Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. (PROF) is a commercial-stage medical device company that regularly issues news on its AI-powered, MRI-guided, incision-free therapies for tissue ablation. The company’s updates frequently center on its TULSA-PRO system and the TULSA Procedure™, which are used to treat prostate cancer and benign prostatic hyperplasia (BPH) using robotically controlled, transurethral ultrasound under real-time MRI guidance.
News coverage for Profound often highlights new clinical milestones, such as first commercial TULSA-PRO cases at major academic hospitals, expansion of TULSA-PRO programs at imaging suites, and recognition of clinical trial data comparing the TULSA Procedure to robotic radical prostatectomy. Releases also describe real-world experience across the prostate disease spectrum, including cancer-only, hybrid cancer and BPH cases, BPH-only patients, and salvage therapy for radio-recurrent localized prostate cancer.
Investors and clinicians following PROF can also expect announcements on regulatory and commercial developments. These include exclusive distribution and supply agreements for TULSA-PRO and Sonalleve in regions such as Canada, Saudi Arabia, Australia and New Zealand, as well as financing transactions like registered direct offerings and private placements used to support sales expansion, research and development, and working capital.
In addition, Profound’s news flow covers product enhancements such as the TULSA-AI® Volume Reduction module for BPH, new clinical data presented at medical meetings, and updates on the installed base and qualified sales pipeline for TULSA-PRO systems. This page aggregates these company-issued releases and related coverage, offering a single location to review the latest developments affecting Profound Medical’s technologies, commercial footprint and capital markets activity.
Profound Medical (NASDAQ:PROF) will launch the TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) at RSNA, Nov 30–Dec 4, 2025, and present new TULSA-PRO clinical data at RSNA and SUO (Dec 2–5, 2025).
The AI-powered module is described as optimizing BPH treatment workflow, reducing procedure times, and enabling multiple same-day cases with existing hardware and reimbursement codes. Company cites pilot trial success, CAPTAIN perioperative data comparing TULSA favorably to robotic prostatectomy on blood loss, length of stay, post-op pain and recovery, and projects a total available prostate-disease market of ~600,000 patients annually.
Profound Medical (NASDAQ:PROF) announced that The Hong Center Scottsdale, led by Dr. Y. Mark Hong, reached a world-first milestone of 200 independent TULSA Procedures performed by a urologist without radiologist involvement on Nov 18, 2025. The milestone highlights a urology-led, MRI-guided, incision-free workflow using the TULSA-PRO system, which offers real-time MRI thermography, autonomous temperature control, and robotically controlled directional ultrasound to ablate prostate tissue while protecting nearby structures.
The announcement notes consistent high-volume experience across whole-gland, focal, BPH and salvage cases, with no procedural blood loss or hospitalization reported and an emphasis on preserved urinary and sexual function.
Profound Medical (NASDAQ:PROF) reported record Q3 2025 revenue of $5.3M, up 87% YoY, driven by $4.1M recurring non-capital revenue and $1.2M capital equipment sales. Gross margin expanded 1,119 bps to 74.3% on manufacturing efficiency. Installed base reached 70 systems with a qualified pipeline of 93 new systems; the company expects at least 75 installs by year-end. Q3 net loss improved to $8.0M ($0.26/share) from $9.4M a year ago. Cash was approximately $24.8M as of September 30, 2025. The company announced new distribution agreements and clinical program milestones to support adoption.
Profound Medical (NASDAQ:PROF) announced an exclusive distribution and supply agreement with Getz Healthcare to commercialize the TULSA-PRO system in Australia and New Zealand, dated November 12, 2025. TULSA-PRO is an AI-powered, MRI-guided, robotically controlled system for prostate ablation that enables real-time MRI thermography and autonomous temperature control.
The partnership aims to expand access to incision-free prostate therapy in Australasia while Profound continues direct sales in North America and seeks further APAC distribution opportunities with Getz Healthcare.
Profound Medical (NASDAQ:PROF) announced an exclusive distribution and supply agreement with Al Faisaliah Medical Systems for its incision-free, MRI-guided TULSA-PRO and Sonalleve technologies in Saudi Arabia on Nov 11, 2025. All required import and sales regulatory approvals for Saudi Arabia are in place. TULSA-PRO has an installed base of 67 systems (Oct 2025) and >4,000 men treated; Sonalleve has 10 devices operational globally and >4,000 women treated for uterine conditions. The deal targets the Kingdom’s large healthcare market and leverages FMS’s regional distribution capabilities.
Profound Medical (NASDAQ:PROF) regained exclusive Canadian distribution rights for the TULSA-PRO system from Knight effective Nov 10, 2025, in exchange for a one-time payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years. Currently only Sunnybrook Health Sciences Centre in Toronto offers the TULSA Procedure and has performed >100 procedures. Profound plans to deploy its North American direct sales team, pursue additional Canadian sites through a concierge model, and use upcoming CAPTAIN trial results (readouts starting 2026) to support provincial coverage applications.
Profound Medical (NASDAQ:PROF) announced real-world data from the Busch Center marking its 500th TULSA Procedure on Oct 16, 2025. The center reported a mix of indications: ~50% primary prostate cancer, ~33% BPH, and remaining salvage cases.
Key outcomes include whole-gland ablations covering >90% of prostate in >75% of cases, treatment volumes up to 250 cc, >15% high-risk cancers treated, and a retrospective PSA fall from 6.7 to 0.9 ng/mL with 93% no residual disease. Reported functional outcomes: 100% pad-free continence and 82% preserved erectile function in the analyzed cohort.
Profound Medical (NASDAQ:PROF) will present an update at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 1:20 p.m. ET in New York City. Management's presentation will be broadcast live and later archived on the company's investor website under News & Events.
The company describes itself as a commercial-stage medical device maker of customizable, AI-powered, incision-free therapies for tissue ablation.
Profound Medical (NASDAQ:PROF) announced preliminary unaudited Q3 2025 revenue of $5.2M–$5.3M, representing 84%–87% YoY growth versus $2.8M in Q3 2024. Gross margin is expected to be ~72%, up from 64% a year ago. The company reported its TULSA-PRO installed base at 67, up from 60, and said it still expects to reach at least 75 systems by year-end.
These figures are preliminary and unaudited; full Q3 2025 results will be released after market close on November 13, 2025, followed by a conference call at 4:30 p.m. ET.
Profound Medical Corp. (NASDAQ:PROF) announced a groundbreaking partnership between Texas Prostate and Dallas Medical Center to launch a first-of-its-kind TULSA program. The collaboration expands Medicare patient access to the TULSA Procedure™, an advanced, AI-powered prostate treatment technology.
The program enables Texas Prostate to perform TULSA procedures at Dallas Medical Center's MRI suite, treating both prostate cancer and benign prostatic hyperplasia (BPH). This advancement follows Medicare's coverage approval in January 2025 for TULSA procedures across various healthcare settings.
The TULSA-PRO® system represents a significant innovation in prostate care, utilizing robotically-guided ultrasound within an MRI environment to precisely ablate targeted prostate tissue. The procedure offers key advantages including same-day discharge, no procedural blood loss, and reduced risk of complications like incontinence or erectile dysfunction.
FAQ
What is the current stock price of Profound Med (PROF)?
What is the market cap of Profound Med (PROF)?
